Raymond James & Associates Myovant Sciences Ltd. Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$24.03 - $27.02 $507,850 - $571,040	21,134 New	21,134 $569,000
Q3 2021 Nov 02, 2021	SELL	$18.94 - $26.99 $1.42 Million - $2.03 Million	-75,086 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$17.07 - $24.56 $2,475 - $3,561	-145 Reduced 0.19%	75,086 $1.71 Million
Q1 2021 May 14, 2021	SELL	$20.46 - $25.18 $250,103 - $307,800	-12,224 Reduced 13.98%	75,231 $1.55 Million
Q4 2020 Feb 12, 2021	SELL	$13.8 - $27.62 $28,179 - $56,400	-2,042 Reduced 2.28%	87,455 $2.42 Million
Q3 2020 Nov 04, 2020	SELL	$14.05 - $22.6 $60,358 - $97,089	-4,296 Reduced 4.58%	89,497 $1.26 Million
Q2 2020 Jul 28, 2020	BUY	$7.34 - $20.84 $1,820 - $5,168	248 Added 0.27%	93,793 $1.93 Million
Q1 2020 Apr 21, 2020	SELL	$6.55 - $14.76 $68,165 - $153,607	-10,407 Reduced 10.01%	93,545 $706,000
Q4 2019 Feb 12, 2020	BUY	$4.2 - $19.21 $436,598 - $2 Million	103,952 New	103,952 $1.61 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.